Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells

Haley L. Peters, Amit Tuli, Xiaojian Wang, Cuiling Liu, Zenggang Pan, Michel M Ouellette, Michael A Hollingsworth, Richard G MacDonald, Joyce C Solheim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In some cellular systems, particularly neurons, amyloid precursor-like protein 2 (APLP2), and its highly homologous family member amyloid precursor protein (APP), have been linked to cellular growth. APLP2 and APP undergo regulated intramembrane proteolysis to produce C-terminal fragments. In this study, we found comprehensive expression of APLP2 C-terminal fragments in a panel of pancreatic cancer cell lines; however, APP C-terminal fragments were notably limited to the BxPC3 cell line. Extensive glycosaminoglycan modification on APLP2 was also found in the majority of pancreatic cancer cell lines. Glycosaminoglycan-modified and -unmodified APLP2, and particularly APLP2 C-terminal fragments, also demonstrated increased expression in oncogene-transformed pancreatic ductal cells. Additionally, elevated APLP2 levels were confirmed in human pancreatic cancer tissue. Downregulation of APLP2 and APP expression, alone or in combination, caused a decrease in the growth of a pancreatic cancer cell line with representatively low APP C-terminal fragment expression, the S2-013 cell line. Furthermore, we found that treatment with β-secretase inhibitors to block formation of APLP2 C-terminal fragments decreased the growth and viability of S2-013 cells, without affecting the survival of a non-transformed pancreatic ductal cell line. In conclusion, our studies demonstrate that abundant APLP2, but not APP, C-terminal fragment expression is conserved in pancreatic cancer cell lines; however, APP and APLP2 equally regulated the growth of S2-013 pancreatic cancer cells. Chiefly, our discoveries establish a role for APLP2 in the growth of pancreatic cancer cells and show that inhibitors preventing APLP2 cleavage reduce the viability of pancreatic cancer cells.

Original languageEnglish (US)
Pages (from-to)1464-1474
Number of pages11
JournalInternational journal of oncology
Volume41
Issue number4
DOIs
StatePublished - Oct 1 2012

Fingerprint

Amyloid beta-Protein Precursor
Protein C
Pancreatic Neoplasms
Amyloid
Cell Line
Growth
Glycosaminoglycans
Amyloid Precursor Protein Secretases
Oncogenes
Proteolysis

Keywords

  • Amyloid precursor protein
  • Amyloid precursor-like protein 2
  • Pancreatic cancer
  • β-site APP cleaving enzyme

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells. / Peters, Haley L.; Tuli, Amit; Wang, Xiaojian; Liu, Cuiling; Pan, Zenggang; Ouellette, Michel M; Hollingsworth, Michael A; MacDonald, Richard G; Solheim, Joyce C.

In: International journal of oncology, Vol. 41, No. 4, 01.10.2012, p. 1464-1474.

Research output: Contribution to journalArticle

@article{237bf2bfd54d4b738392f6603d30ab09,
title = "Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells",
abstract = "In some cellular systems, particularly neurons, amyloid precursor-like protein 2 (APLP2), and its highly homologous family member amyloid precursor protein (APP), have been linked to cellular growth. APLP2 and APP undergo regulated intramembrane proteolysis to produce C-terminal fragments. In this study, we found comprehensive expression of APLP2 C-terminal fragments in a panel of pancreatic cancer cell lines; however, APP C-terminal fragments were notably limited to the BxPC3 cell line. Extensive glycosaminoglycan modification on APLP2 was also found in the majority of pancreatic cancer cell lines. Glycosaminoglycan-modified and -unmodified APLP2, and particularly APLP2 C-terminal fragments, also demonstrated increased expression in oncogene-transformed pancreatic ductal cells. Additionally, elevated APLP2 levels were confirmed in human pancreatic cancer tissue. Downregulation of APLP2 and APP expression, alone or in combination, caused a decrease in the growth of a pancreatic cancer cell line with representatively low APP C-terminal fragment expression, the S2-013 cell line. Furthermore, we found that treatment with β-secretase inhibitors to block formation of APLP2 C-terminal fragments decreased the growth and viability of S2-013 cells, without affecting the survival of a non-transformed pancreatic ductal cell line. In conclusion, our studies demonstrate that abundant APLP2, but not APP, C-terminal fragment expression is conserved in pancreatic cancer cell lines; however, APP and APLP2 equally regulated the growth of S2-013 pancreatic cancer cells. Chiefly, our discoveries establish a role for APLP2 in the growth of pancreatic cancer cells and show that inhibitors preventing APLP2 cleavage reduce the viability of pancreatic cancer cells.",
keywords = "Amyloid precursor protein, Amyloid precursor-like protein 2, Pancreatic cancer, β-site APP cleaving enzyme",
author = "Peters, {Haley L.} and Amit Tuli and Xiaojian Wang and Cuiling Liu and Zenggang Pan and Ouellette, {Michel M} and Hollingsworth, {Michael A} and MacDonald, {Richard G} and Solheim, {Joyce C}",
year = "2012",
month = "10",
day = "1",
doi = "10.3892/ijo.2012.1553",
language = "English (US)",
volume = "41",
pages = "1464--1474",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells

AU - Peters, Haley L.

AU - Tuli, Amit

AU - Wang, Xiaojian

AU - Liu, Cuiling

AU - Pan, Zenggang

AU - Ouellette, Michel M

AU - Hollingsworth, Michael A

AU - MacDonald, Richard G

AU - Solheim, Joyce C

PY - 2012/10/1

Y1 - 2012/10/1

N2 - In some cellular systems, particularly neurons, amyloid precursor-like protein 2 (APLP2), and its highly homologous family member amyloid precursor protein (APP), have been linked to cellular growth. APLP2 and APP undergo regulated intramembrane proteolysis to produce C-terminal fragments. In this study, we found comprehensive expression of APLP2 C-terminal fragments in a panel of pancreatic cancer cell lines; however, APP C-terminal fragments were notably limited to the BxPC3 cell line. Extensive glycosaminoglycan modification on APLP2 was also found in the majority of pancreatic cancer cell lines. Glycosaminoglycan-modified and -unmodified APLP2, and particularly APLP2 C-terminal fragments, also demonstrated increased expression in oncogene-transformed pancreatic ductal cells. Additionally, elevated APLP2 levels were confirmed in human pancreatic cancer tissue. Downregulation of APLP2 and APP expression, alone or in combination, caused a decrease in the growth of a pancreatic cancer cell line with representatively low APP C-terminal fragment expression, the S2-013 cell line. Furthermore, we found that treatment with β-secretase inhibitors to block formation of APLP2 C-terminal fragments decreased the growth and viability of S2-013 cells, without affecting the survival of a non-transformed pancreatic ductal cell line. In conclusion, our studies demonstrate that abundant APLP2, but not APP, C-terminal fragment expression is conserved in pancreatic cancer cell lines; however, APP and APLP2 equally regulated the growth of S2-013 pancreatic cancer cells. Chiefly, our discoveries establish a role for APLP2 in the growth of pancreatic cancer cells and show that inhibitors preventing APLP2 cleavage reduce the viability of pancreatic cancer cells.

AB - In some cellular systems, particularly neurons, amyloid precursor-like protein 2 (APLP2), and its highly homologous family member amyloid precursor protein (APP), have been linked to cellular growth. APLP2 and APP undergo regulated intramembrane proteolysis to produce C-terminal fragments. In this study, we found comprehensive expression of APLP2 C-terminal fragments in a panel of pancreatic cancer cell lines; however, APP C-terminal fragments were notably limited to the BxPC3 cell line. Extensive glycosaminoglycan modification on APLP2 was also found in the majority of pancreatic cancer cell lines. Glycosaminoglycan-modified and -unmodified APLP2, and particularly APLP2 C-terminal fragments, also demonstrated increased expression in oncogene-transformed pancreatic ductal cells. Additionally, elevated APLP2 levels were confirmed in human pancreatic cancer tissue. Downregulation of APLP2 and APP expression, alone or in combination, caused a decrease in the growth of a pancreatic cancer cell line with representatively low APP C-terminal fragment expression, the S2-013 cell line. Furthermore, we found that treatment with β-secretase inhibitors to block formation of APLP2 C-terminal fragments decreased the growth and viability of S2-013 cells, without affecting the survival of a non-transformed pancreatic ductal cell line. In conclusion, our studies demonstrate that abundant APLP2, but not APP, C-terminal fragment expression is conserved in pancreatic cancer cell lines; however, APP and APLP2 equally regulated the growth of S2-013 pancreatic cancer cells. Chiefly, our discoveries establish a role for APLP2 in the growth of pancreatic cancer cells and show that inhibitors preventing APLP2 cleavage reduce the viability of pancreatic cancer cells.

KW - Amyloid precursor protein

KW - Amyloid precursor-like protein 2

KW - Pancreatic cancer

KW - β-site APP cleaving enzyme

UR - http://www.scopus.com/inward/record.url?scp=84866505151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866505151&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1553

DO - 10.3892/ijo.2012.1553

M3 - Article

C2 - 22797723

AN - SCOPUS:84866505151

VL - 41

SP - 1464

EP - 1474

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -